The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
Open accessAbstract
Background: The efficacy of ceftazidime-avibactam-a cephalosporin-β-lactamase inhibitor combination with in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE)-compared with colistin remains unknown. Methods: Patients initially treated with either ceftazidime-avibactam or colistin for CRE infections were selected from the Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE), a prospective, multicenter, observational study. Efficacy, safety, and benefit-risk analyses were performed using intent-to-treat analyses with partial credit and the desirability of outcome ranking approaches. The ordinal efficacy outcome was based on disposition at day 30 after starting treatment (home vs not home but not observed to die in the hospital vs hospital death). All analyses were adjusted for confounding using inverse probability of treatment weighting (IPTW). Results: Thirty-eight patients were treated first with ceftazidime-avibactam and 99 with colistin. Most patients received additional anti-CRE agents as part of their treatment. Bloodstream (n = 63; 46%) and respiratory (n = 30; 22%) infections were most common. In patients treated with ceftazidime-avibactam versus colistin, IPTW-adjusted all-cause hospital mortality 30 days after starting treatment was 9% versus 32%, respectively (difference, 23%; 95% bootstrap confidence interval, 9%-35%; P = .001). In an analysis of disposition at 30 days, patients treated with ceftazidime-avibactam, compared with those treated within colistin, had an IPTW-adjusted probability of a better outcome of 64% (95% confidence interval, 57%-71%). Partial credit analyses indicated uniform superiority of ceftazidime-avibactam to colistin. Conclusions: Ceftazidime-avibactam may be a reasonable alternative to colistin in the treatment of K. pneumoniae carbapenemase-producing CRE infections. These findings require confirmation in a randomized controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Marginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581
Liu, Y.-Y., Wang, Y., Walsh, T. R., Yi, L.-X., Zhang, R., Spencer, J., Doi, Y., Tian, G., Dong, B., Huang, X., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00424-7 · Cited by 5,398
Self-citationPerformance standards for antimicrobial susceptibility testing
Weinstein, M. P., & Clinical (2019) · Clinical and Laboratory Standards Institute eBooks · Cited by 4,341
Hernán, M. Á., Brumback, B., & Robins, J. M. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00012 · Cited by 1,782
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70190-7 · Cited by 1,627
Self-citationvan Duin, D., & Bonomo, R. A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw243 · Cited by 549
Self-citationGutiérrez-Gutiérrez, B., Salamanca, E., de Cueto, M., Hsueh, P.-R., Viale, P., Paño-Pardo, J. R., Venditti, M., Tumbarello, M., Daikos, G., Cantón, R., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30228-1 · Cited by 512
Self-citationTumbarello, M., Trecarichi, E. M., De Rosa, F. G., Giannella, M., Giacobbe, D. R., Bassetti, M., Losito, A. R., Bartoletti, M., Del Bono, V., Corcione, S., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv086 · Cited by 511
Shields, R. K., Potoski, B. A., Haidar, G., Hao, B., Doi, Y., Chen, L., Press, E. G., Kreiswirth, B. N., Clancy, C. J., & Nguyen, M. H. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw636 · Cited by 430
Self-citation
Cited by
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Self-citationPaul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., de Waele, J., Daikos, G. L., Akova, M., Harbarth, S., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.025 · Cited by 1,056
Self-citationESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad428 · Cited by 740
Self-citationRodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
Carbapenemase-Producing Organisms: A Global Scourge
Bonomo, R. A., Burd, E. M., Conly, J., Limbago, B. M., Poirel, L., Segre, J. A., & Westblade, L. F. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix893 · Cited by 656
Self-citationInterplay between β-lactamases and new β-lactamase inhibitors
Bush, K., & Bradford, P. A. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0159-8 · Cited by 531
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac268 · Cited by 526
Self-citationNew β-Lactam–β-Lactamase Inhibitor Combinations
Yahav, D., Giske, C. G., Grāmatniece, A., Abodakpi, H., Tam, V. H., & Leibovici, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-20 · Cited by 521
Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
Sheu, C.-C., Chang, Y.-T., Lin, S.-Y., Chen, Y.-H., & Hsueh, P.-R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00080 · Cited by 520
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1478 · Cited by 441
Self-citationTamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab295 · Cited by 390
Self-citationWang, M., Earley, M., Chen, L., Hanson, B. M., Yu, Y., Liu, Z., Salcedo, S., Cober, E., Li, L., Kanj, S. S., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00399-6 · Cited by 363
Self-citationTumbarello, M., Trecarichi, E. M., Corona, A., De Rosa, F. G., Bassetti, M., Mussini, C., Menichetti, F., Viscoli, C., Campoli, C., Venditti, M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy492 · Cited by 354
Present and Future of Carbapenem-resistant Enterobacteriaceae (CRE) Infections
Suay-García, B., & Pérez-Gracia, M. T. (2019) · Antibiotics · doi:10.3390/antibiotics8030122 · Cited by 344
van Duin, D., Arias, C. A., Komarow, L., Chen, L., Hanson, B. M., Weston, G., Cober, E., Garner, O. B., Jacob, J. T., Satlin, M. J., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30755-8 · Cited by 337
Self-citationBoyd, S. E., Livermore, D. M., Hooper, D. C., & Hope, W. W. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00397-20 · Cited by 315
Multidrug-resistant Gram-negative bacterial infections
Macesic, N., Uhlemann, A.-C., & Peleg, A. Y. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02081-6 · Cited by 315
Key takeaways from the U.S. CDC’s 2019 antibiotic resistance threats report for frontline providers
Kadri, S. S. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004371 · Cited by 292
Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Kreiswirth, B. N., & Clancy, C. J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02497-17 · Cited by 289
The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019) · Frontiers in Public Health · doi:10.3389/fpubh.2019.00151 · Cited by 288
Tumbarello, M., Raffaelli, F., Giannella, M., Mantengoli, E., Mularoni, A., Venditti, M., De Rosa, F. G., Sarmati, L., Bassetti, M., Brindicci, G., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab176 · Cited by 275
Management of carbapenem-resistant Enterobacteriaceae infections
Durante-Mangoni, E., Andini, R., & Zampino, R. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.013 · Cited by 261
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
Wu, J. Y., Srinivas, P., & Pogue, J. M. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00286-6 · Cited by 195
Metadata
- Authors
- van Duin, D., Lok, J. J., Earley, M., Cober, E., Richter, S. S., Perez, F., Salata, R. A., Kalayjian, R. C., Watkins, R. R., Doi, Y., Kaye, K. S., Fowler, V. G., Paterson, D. L., Bonomo, R. A., Evans, S., & Antibacterial Resistance Leadership Group
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-09-04
- Volume
- 66
- Issue
- 2
- Pages
- 163-171
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2766370714
- Cited by
- 655
- References
- 26
- FWCI
- 21.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.